💊 This facility specializes in small-scale, innovative drug projects, including antibody-drug conjugates.
🌍 The acquisition supports Ofichem’s strategic shift towards serving biotech firms and expands its client base in the Nordic region.
🔗 It aligns with Ofichem’s goal of seamless research-to-production processes.
Introduction:
The article discusses Ofichem’s acquisition of Meribel Pharma Solutions’ facility located in Uppsala, Sweden. This strategic move is aimed at enhancing Ofichem’s capabilities in early-phase drug substance development and broadening its non-GMP services in the small-molecule sector.
- Ofichem, based in the Netherlands, has acquired the Uppsala site from Meribel Pharma Solutions, which specializes in early-phase drug development.
- The Uppsala facility, previously known as OT Chemistry, develops small-scale, early-phase projects and includes expertise in traditional small molecules and innovative modalities like antibody-drug conjugates, oligonucleotides, and PROTACs.
- This acquisition is part of Ofichem’s strategy to enhance its service offerings for biotech innovators, shifting focus from primarily serving generics and mid-sized pharma.
- The integration of this site with Ofichem’s GMP operations in Ter Apel creates a streamlined process from validation research to commercial production.
- The acquisition allows Ofichem access to a portfolio of over 40 biotech and mid-sized pharma clients and strengthens its market presence in the Nordic region.
Conclusion:
The acquisition of Meribel’s Uppsala facility represents a significant step in Ofichem’s strategic evolution towards supporting early-stage drug development for innovative biotech companies. With enhanced capabilities and a stronger client base, Ofichem is poised to create an integrated pathway from research to market for emerging therapeutic solutions.
